Lucis, a preventive healthcare platform, has raised $20 million in Series A funding led by Singular, with participation from General Catalyst, Y Combinator and angel investors. The round follows an $8 million seed raised four months ago, bringing total funding to $28 million. Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis analyses over 110 blood biomarkers and uses AI-powered insights reviewed by physicians to deliver personalised health guidance. Among users completing six-month follow-ups, 75% improved at least three biomarkers without medication, whilst over 80% opted to retest. The platform has reached 10,000 users across France, the UK, Ireland and Portugal, delivering over one million biomarker tests. Lucis plans to expand into Spain, Germany and Italy by end-2026.

Lucis Life has raised $8.5 million in a seed funding round, led by founder Julien Bouteloup. The healthcare and longevity company achieved this milestone just one year after its launch. The funding round signals growing investor confidence in healthcare innovation. Bouteloup, known for his advocacy around addressing challenges beyond financial returns, has positioned Lucis Life as a leading innovator in the longevity sector. Details about participating investors and specific plans for the capital were not disclosed.